Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.

Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW.

Cell Death Differ. 2010 Sep;17(9):1381-91. doi: 10.1038/cdd.2010.25. Epub 2010 Mar 19.

2.

Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.

McCaig AM, Cosimo E, Leach MT, Michie AM.

Br J Haematol. 2011 Apr;153(2):199-211. doi: 10.1111/j.1365-2141.2010.08507.x. Epub 2011 Feb 24.

PMID:
21352196
3.

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.

Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP.

Blood. 2008 Feb 1;111(3):1366-77. Epub 2007 Oct 25.

4.

Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids.

Petrillo MG, Fettucciari K, Montuschi P, Ronchetti S, Cari L, Migliorati G, Mazzon E, Bereshchenko O, Bruscoli S, Nocentini G, Riccardi C.

BMC Pharmacol Toxicol. 2014 Jul 3;15:35. doi: 10.1186/2050-6511-15-35.

5.

Subcellular distribution of Lck during CD4 T-cell maturation in the thymic medulla regulates the T-cell activation threshold.

Stephen TL, Wilson BS, Laufer TM.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7415-20. doi: 10.1073/pnas.1119272109. Epub 2012 Apr 23.

6.

Glucocorticoid-mediated inhibition of Lck modulates the pattern of T cell receptor-induced calcium signals by down-regulating inositol 1,4,5-trisphosphate receptors.

Harr MW, Rong Y, Bootman MD, Roderick HL, Distelhorst CW.

J Biol Chem. 2009 Nov 13;284(46):31860-71. doi: 10.1074/jbc.M109.005579. Epub 2009 Sep 23.

7.

Lck is a key target of imatinib and dasatinib in T-cell activation.

Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ.

Leukemia. 2010 Apr;24(4):896-900. doi: 10.1038/leu.2010.11. Epub 2010 Feb 11. No abstract available.

PMID:
20147973
8.

Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.

Nerreter T, Distler E, Köchel C, Einsele H, Herr W, Seggewiss-Bernhardt R.

Exp Hematol. 2013 Jul;41(7):604-614.e4. doi: 10.1016/j.exphem.2013.02.013. Epub 2013 Mar 4.

PMID:
23466625
9.

Superantigen-induced steroid resistance depends on activation of phospholipase Cβ2.

Verhaar AP, Wildenberg ME, Duijvestein M, Vos AC, Peppelenbosch MP, Löwenberg M, Hommes DW, van den Brink GR.

J Immunol. 2013 Jun 15;190(12):6589-95. doi: 10.4049/jimmunol.1202898. Epub 2013 May 20.

10.

Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.

Huber S, Oelsner M, Decker T, zum Büschenfelde CM, Wagner M, Lutzny G, Kuhnt T, Schmidt B, Oostendorp RA, Peschel C, Ringshausen I.

Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.

PMID:
21293487
11.

Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.

Martinez Marignac VL, Smith S, Toban N, Bazile M, Aloyz R.

Oncotarget. 2013 Dec;4(12):2550-66.

12.

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L, Lee FY, Knowles DM, Coleman M, Wang YL.

Clin Cancer Res. 2010 Jan 15;16(2):587-99. doi: 10.1158/1078-0432.CCR-09-1519. Epub 2010 Jan 12.

13.

LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells.

Talab F, Allen JC, Thompson V, Lin K, Slupsky JR.

Mol Cancer Res. 2013 May;11(5):541-54. doi: 10.1158/1541-7786.MCR-12-0415-T. Epub 2013 Mar 15.

14.

Inhibition of p56(lck) tyrosine kinase by isothiazolones.

Trevillyan JM, Chiou XG, Ballaron SJ, Tang QM, Buko A, Sheets MP, Smith ML, Putman CB, Wiedeman P, Tu N, Madar D, Smith HT, Gubbins EJ, Warrior UP, Chen YW, Mollison KW, Faltynek CR, Djurić SW.

Arch Biochem Biophys. 1999 Apr 1;364(1):19-29.

PMID:
10087161
15.
16.

Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

de Frias M, Iglesias-Serret D, Cosialls AM, Coll-Mulet L, Santidrián AF, González-Gironès DM, de la Banda E, Pons G, Gil J.

Haematologica. 2009 Dec;94(12):1698-707. doi: 10.3324/haematol.2008.004028. Epub 2009 Oct 8.

17.

Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN.

Löwenberg M, Verhaar AP, Bilderbeek J, Marle Jv, Buttgereit F, Peppelenbosch MP, van Deventer SJ, Hommes DW.

EMBO Rep. 2006 Oct;7(10):1023-9. Epub 2006 Aug 4.

18.

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.

Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.

Mol Cancer Ther. 2007 Apr;6(4):1400-5.

19.

Profound inhibition of antigen-specific T-cell effector functions by dasatinib.

Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R.

Clin Cancer Res. 2008 Apr 15;14(8):2484-91. doi: 10.1158/1078-0432.CCR-07-4393.

20.

Dexamethasone augments CXCR4-mediated signaling in resting human T cells via the activation of the Src kinase Lck.

Ghosh MC, Baatar D, Collins G, Carter A, Indig F, Biragyn A, Taub DD.

Blood. 2009 Jan 15;113(3):575-84. doi: 10.1182/blood-2008-04-151803. Epub 2008 Oct 7.

Supplemental Content

Support Center